Scarica l'app Stockscreener
6.50
4.17%
0.26
Dopo l'orario di chiusura:
6.41
-0.09
-1.38%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$6.24
Aprire:
$6.23
Volume 24 ore:
1.23M
Relative Volume:
0.57
Capitalizzazione di mercato:
$489.58M
Reddito:
$3.64M
Utile/perdita netta:
$-87.37M
Rapporto P/E:
-1.5815
EPS:
-4.11
Flusso di cassa netto:
$-86.46M
1 W Prestazione:
-2.26%
1M Prestazione:
-19.35%
6M Prestazione:
+5.86%
1 anno Prestazione:
+14.24%
Intervallo 1D:
$6.19
$6.53
Intervallo di 1 settimana:
$6.14
$6.78
Portata 52W:
$4.01
$11.24
Verastem Inc Stock (VSTM) Company Profile
Nome
Verastem Inc
Settore
Industria
Telefono
(781) 292-4200
Indirizzo
117 KENDRICK STREET, NEEDHAM, MA
Confronta VSTM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VSTM
Verastem Inc
|
6.50 | 470.00M | 3.64M | -87.37M | -86.46M | -4.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-16 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-04-10 | Iniziato | Jefferies | Buy |
| 2025-03-24 | Reiterato | H.C. Wainwright | Buy |
| 2024-12-31 | Reiterato | BTIG Research | Buy |
| 2024-09-30 | Iniziato | Guggenheim | Buy |
| 2023-11-21 | Ripresa | BTIG Research | Buy |
| 2023-09-27 | Iniziato | B. Riley Securities | Buy |
| 2023-06-15 | Aggiornamento | Mizuho | Neutral → Buy |
| 2022-09-07 | Ripresa | Alliance Global Partners | Buy |
| 2022-04-29 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-04-14 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-03-09 | Iniziato | Truist | Buy |
| 2021-07-01 | Iniziato | Alliance Global Partners | Buy |
| 2021-05-24 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2019-06-20 | Downgrade | BTIG Research | Buy → Neutral |
| 2019-05-10 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2018-07-13 | Iniziato | BTIG Research | Buy |
| 2018-05-02 | Iniziato | Seaport Global Securities | Buy |
| 2018-03-08 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-09-07 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-13 | Iniziato | Oppenheimer | Outperform |
| 2017-03-24 | Reiterato | H.C. Wainwright | Buy |
| 2015-09-29 | Downgrade | Cantor Fitzgerald | Buy → Hold |
| 2015-09-29 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2015-09-29 | Downgrade | Jefferies | Buy → Hold |
| 2015-09-29 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2015-09-28 | Downgrade | Mizuho | Buy → Neutral |
| 2015-09-28 | Downgrade | ROTH Capital | Buy → Neutral |
| 2015-09-09 | Iniziato | Raymond James | Strong Buy |
| 2015-05-12 | Reiterato | UBS | Buy |
| 2015-04-08 | Iniziato | H.C. Wainwright | Buy |
| 2015-01-23 | Reiterato | ROTH Capital | Buy |
| 2014-07-08 | Ripresa | Oppenheimer | Perform |
| 2014-02-11 | Iniziato | Mizuho | Buy |
Mostra tutto
Verastem Inc Borsa (VSTM) Ultime notizie
Breakout Zone: What is the Moat Score of Verastem IncJuly 2025 Market Mood & Safe Capital Growth Tips - baoquankhu1.vn
Microvast, Datavault AI, RH, Becton Dickinson, Verastem Shake-Up - TipRanks
Retail Trends: Does Verastem Inc have a competitive edgeJuly 2025 Levels & Risk Controlled Swing Alerts - baoquankhu1.vn
Have Verastem Insiders Been Selling Stock? - simplywall.st
CEO Change: Is Icahn Enterprises LP showing insider buyingJuly 2025 Chart Watch & Accurate Buy Signal Notifications - baoquankhu1.vn
Resistance Check: Does Verastem Inc outperform in volatile markets2025 Market Outlook & Real-Time Volume Trigger Notifications - baoquankhu1.vn
Insider Sell: Dan Paterson Sells Shares of Verastem Inc (VSTM) - GuruFocus
Daniel Calkins Sells 5,039 Shares of Verastem (NASDAQ:VSTM) Stock - MarketBeat
Insider Selling: Verastem (NASDAQ:VSTM) CEO Sells 10,321 Shares of Stock - MarketBeat
EPS Watch: Why Verastem Inc stock is trending among retail tradersTrade Risk Assessment & Reliable Entry Point Alerts - Bộ Nội Vụ
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Chartmill
Polar Capital Holdings Plc Increases Stake in Verastem Inc - GuruFocus
Verastem, Inc. (VSTM) Investor Outlook: Biotech Stock With Over 100% Potential Upside - directorstalkinterviews.com
Can Verastem Inc. stock continue upward trendJuly 2025 Price Swings & Consistent Income Trade Recommendations - Улправда
Is Verastem Inc. stock attractive after correctionMarket Performance Recap & Verified Short-Term Trading Plans - ulpravda.ru
Will Verastem Inc. stock attract more institutional investorsJuly 2025 Outlook & Safe Entry Point Identification - Улправда
Verastem updates oncology strategy in new corporate presentation - TipRanks
RBC Raises Price Target on Verastem to $15 From $14, Keeps Outperform, Speculative Risk - marketscreener.com
Immuneering plummets following phase 2 data of atebimetinib for pancreatic cancer - Seeking Alpha
Verastem (NASDAQ:VSTM) Shares Up 19.3%Should You Buy? - MarketBeat
Verastem shifts focus to KRAS G12D and pancreatic programs - MSN
Verastem Advances with Phase 3 Trial Progress and Product Launch Boosting Prospects - MSN
What's Going On With Verastem Stock Friday?Verastem (NASDAQ:VSTM) - Benzinga
Verastem ends trial of Avmapki Fakzynja combo with Amgen's Lumakras in NSCLC - MSN
Verastem Oncology stock drops after hours after discontinuing a clinical trial in lung cancer - MSN
Verastem stock steady as Mizuho reiterates Outperform rating By Investing.com - Investing.com Canada
Verastem Shifts Focus to KRAS G12D and Pancreatic Programs - TipRanks
Verastem to discontinue Avmapki/Fakzynja combo in KRAS G12C-mutated NSCLC - The Pharma Letter
Verastem (VSTM) Halts Development of Avutometinib/Defactinib Com - GuruFocus
Verastem: Downgrading To Buy Based On RAMP-203 Setback In Targeting KRAS G12C NSCLC (VSTM) - Seeking Alpha
Amgen stock dips as Lumakras combo trial ends; MariTide data now the next watch - ts2.tech
Verastem (NASDAQ:VSTM) Shares Cross Above 200 Day Moving AverageShould You Sell? - MarketBeat
Verastem, TEN Holdings And 3 Stocks To Watch Heading Into Tuesday - Benzinga
Verastem Oncology (VSTM) Shifts Focus to Promising KRAS G12D Inh - GuruFocus
Calkins, Verastem CFO, sells $628 in shares By Investing.com - Investing.com South Africa
Verastem Oncology provides update on Ramp 203 phase 1/2 clinical trial - marketscreener.com
Verastem Oncology Stock Drops After Hours After Discontinuing A Clinical Trial In Lung Cancer - Stocktwits
Verastem to Discontinue RAMP 203 Clinical Trial in Lung Cancer After Interim Data Read - marketscreener.com
Verastem stock falls after discontinuing KRAS G12C lung cancer trial By Investing.com - Investing.com Nigeria
Verastem (VSTM) Shifts Focus to Promising KRAS G12D Inhibitor in Cancer Treatment - GuruFocus
Verastem stock falls after discontinuing KRAS G12C lung cancer trial - Investing.com
Verastem discontinues KRAS G12C lung cancer trial to focus on G12D - Investing.com Canada
Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer - Business Wire
Calkins, Verastem CFO, sells $628 in shares - Investing.com India
Behavioral Patterns of VSTM and Institutional Flows - Stock Traders Daily
Verastem, Inc.'s (NASDAQ:VSTM) Stock Retreats 26% But Revenues Haven't Escaped The Attention Of Investors - 富途牛牛
Verastem Inc Azioni (VSTM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.09%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):